AcelRx Stock Jumps 20% After Positive Results From Its Trial On ARX-04

AcelRx Pharmaceuticals Inc ACRX disclosed that its investigational product candidate ARX-04 provided solid tolerance level in an open-label Phase three trial for post operative acute pain treatment. This included elderly patients, as well as, organ impairment.

AcelRX indicated it plans to file for NDA this year following the completion of phase three program on ARX-04. The company pointed out that about two out of three patients had no adverse events in the trial irrespective of age and organ function. The most regular adverse events were headache and nausea.

As a method of pain control, the company indicated that 90 percent professionals responded with "good" assessment while 87 percent of patients responded with "excellent."

AcelRx co-founder and Chief Medical Officer, Pamela Palmer, said, "Following short-stay in-hospital surgery, post-operative patients who do not require long-term analgesia still need safe and effective short-term pain management for efficient discharge."

The company indicated that both primary and secondary efficacy endpoints demonstrated a drop in intensity of pain starting at 30 minutes after the first dose.

The stock jumped $0.72, or 21.95 percent, to $4.00 in pre-market trading.